TY - JOUR
T1 - Circumferential resection margin involvement in stage III rectal cancer patients treated with curative resection followed by chemoradiotherapy
T2 - A surrogate marker for local recurrence?
AU - Kang, Jeonghyun
AU - Kim, Hyunki
AU - Hur, Hyuk
AU - Min, Byung Soh
AU - Baik, Seung Hyuk
AU - Lee, Kang Young
AU - Sohn, Seung Kook
AU - Kim, Nam Kyu
PY - 2013/1
Y1 - 2013/1
N2 - Purpose: Circumferential resection margin (CRM) involvement is a well-known predictor for poor prognosis in rectal cancer. However, the significance is controversial in some studies. Accordingly, this study attempted to examine the prognostic impact of CRM involvement in stage III rectal cancer. Materials and Methods: Between January 1990 and December 2007, a total of 449 patients who underwent curative resection followed by complete adjuvant chemoradiotherapy for stage III rectal cancer located within 12 cm from the anal verge were selected. Patients were divided into a CRM-positive group (n=79, 17.6%) and a CRM-negative group (n=370, 82.4%). Results: With a median follow-up of 56.6 months, recurrent disease was seen in 53.2 and 43.5% of the CRM-positive and CRM-negative group, respectively. CRM involvement was an independent prognostic factor for 5-year systemic recurrence-free survival (HR: 1.5, CI: 1.0-2.2, p=0.017). However, no significant difference was observed for local recurrence rate between the two groups (13.0 and 13.5%, respectively, p=0.677). Conclusion: In this study, local recurrence rate did not differ according to CRM involvement status in stage III rectal cancer patients, although CRM involvement was shown to be an independent poor prognostic factor. Accordingly, validation of the results of this study by further large prospective randomized trials is warranted.
AB - Purpose: Circumferential resection margin (CRM) involvement is a well-known predictor for poor prognosis in rectal cancer. However, the significance is controversial in some studies. Accordingly, this study attempted to examine the prognostic impact of CRM involvement in stage III rectal cancer. Materials and Methods: Between January 1990 and December 2007, a total of 449 patients who underwent curative resection followed by complete adjuvant chemoradiotherapy for stage III rectal cancer located within 12 cm from the anal verge were selected. Patients were divided into a CRM-positive group (n=79, 17.6%) and a CRM-negative group (n=370, 82.4%). Results: With a median follow-up of 56.6 months, recurrent disease was seen in 53.2 and 43.5% of the CRM-positive and CRM-negative group, respectively. CRM involvement was an independent prognostic factor for 5-year systemic recurrence-free survival (HR: 1.5, CI: 1.0-2.2, p=0.017). However, no significant difference was observed for local recurrence rate between the two groups (13.0 and 13.5%, respectively, p=0.677). Conclusion: In this study, local recurrence rate did not differ according to CRM involvement status in stage III rectal cancer patients, although CRM involvement was shown to be an independent poor prognostic factor. Accordingly, validation of the results of this study by further large prospective randomized trials is warranted.
UR - http://www.scopus.com/inward/record.url?scp=84871277402&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871277402&partnerID=8YFLogxK
U2 - 10.3349/ymj.2013.54.1.131
DO - 10.3349/ymj.2013.54.1.131
M3 - Article
C2 - 23225809
AN - SCOPUS:84871277402
SN - 0513-5796
VL - 54
SP - 131
EP - 138
JO - Yonsei Medical Journal
JF - Yonsei Medical Journal
IS - 1
ER -